Original Research Article I Volume 5 I Issue 4 I 2017

Glycosylated hemoglobin (HBA1c) levels as follow-up for clinical outcome (cardiac events) after coronary artery stenting in diabetic patients

Suzy Fawzi

Biolife; 2017, 5(4), pp 557-563

DOI:https://doi.org/10.5281/zenodo.7393268

Abstract:

Diabetes mellitus (DM) has been recognized to be a strong risk factor for cardiovascular disease (CVD) and has been proved to be an independent risk factor for in-stent restenosis. After stent implantation, restenosis remains the “Achilles’ heel” of percutaneous coronary intervention (PCI) and diabetic patients compared to non-diabetics still have poorer clinical outcomes

Keywords:

Diabetes mellitus, percutaneous coronary intervention (stenting), HbA1c, adverse cardiac events, Stress Thallium.

References:

  1. Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP, Cohen DJ, Hokk. Five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials) Am J Cardiol. 2006; 98: 718-721.doi: 10.1016/j.amjcard.2006.03.059.
  2. Dauerman HL. Percutaneous coronary intervention, diabetes mellitus, and death. J AM CollCardiol 2010; 55: 1076-1079.
  3. Kowalczyk J, Mazurek M, Zielinska T, et al. Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. Eur J Prevent Cardiol 2015; 22: 798-806.
  4. Ueda H, Mitsusada N, Harimoto K, Miyawaki M, Yasuga Y and Hiraoka H. Glycosylatedhemoglobin is a predictor of major adverse cardiac events after drug-eluting stent implantations in patients with diabetes mellitus. Cardiology 2010; 116: 51-57.
  5. Kataska Y, Shao M, et al. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. Eur J PrevCardiol 2013; 20: 209-217.
  6. Zheng J, Cherg J, Zhang Q, Qi C, Wang T, Xiao X. Association between glycosylated hemoglobin level and cardiovascular outcomes in diabetic patients after percutaneous coronary intervention. Medicine (Baltimore) 2016; 95: 19-28: e 3696.
  7. Fatima N, Zaman M, Ishaq M, Baloch DJ, Bano M, et al. Impact of glycosylated hemoglobin (HBA1c) on the extent of perfusion abnormalities and left ventricular using gated myocardial perfusion imaging and clinical outcomes in diabetic patients. Nucl Med Commun2013; 34: 489-494.
  8. Su G, Mi SH, Tao H, Li Z, Yang Hx, etal, Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care 2013; 36: 1026-1032.
  9. Swapna Gurrapu and Estari Mamidala. Medicinal Plants Used By Traditional Medicine
    Practitioners in the Management of HIV/AIDS-Related Diseases in Tribal Areas of Adilabad
    District, Telangana Region. The Ame J Sci & Med Res. 2016:2(1):239-245.
    doi:10.17812/ajsmr2101.
  10. Geng J, Zhang Y, Wang B, Xie J, Xu B, Li J.Glycosylated hemoglobin leveled clinical outcomes in non-diabetic patients with coronary artery disease. Medicine 2017; 96: 17 (e 6784).
  11. Saleem T, Mohammad KH, Abdel-Fattah MM, et al. Association of glycosylated hemoglobin level and diabetes mellitus duration with the severity of coronary artery disease. DiabVasc Dis Res 2008; 5: 184-189.
  12. Timmer JR, Hoekstra M, Nijsten M, et al. Prognostic value of admission glycosylated hemoglobin and glucose in non-diabetic patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. Circulation 2011; 124: 704-711....

Article Dates:

Received: 04 October 2017; Accepted: 24 November 2017; Published: 04 December 2017

How To Cite:

Suzy Fawzi. (2022). Glycosylated hemoglobin (HBA1c) levels as follow-up for clinical outcome (cardiac events) after coronary artery stenting in diabetic patients. Biolife, 5(4), 557–563. https://doi.org/10.5281/zenodo.7393268

Download Full Paper: PDF

Logo


Logo